Clinical Pharmacokinetics and Endocrine Disorders (original) (raw)
Aarbakke J, Bending MR, Davies AS. Increased oxidation of phenylbutasone during hydrocortisone infusion in man. British Journal of Clinical Pharmacology 4: 621–622, 1977 ArticlePubMedCAS Google Scholar
Abernethy DR, Divoll M, Greenblatt DJ, Ameer B. Obesity, sex and acetaminophen disposition. Clinical Pharmacology and Therapeutics 31: 783–790, 1982 ArticlePubMedCAS Google Scholar
Abernethy DR, Greenblatt DJ. Lidocaine disposition in obesity. American Journal of Cardiology 53: 1183–1186, 1984 ArticlePubMedCAS Google Scholar
Abernethy DR, Greenblatt DJ. Ibuprofen disposition in obese individuals. Arthritis and Rheumatism 28: 1117–1121, 1985 ArticlePubMedCAS Google Scholar
Abernethy DR, Greenblatt DJ. Drug disposition in obese humans, an update. Clinical Pharmacokinetics 11: 189–213, 1986 Article Google Scholar
Abernethy DR, Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Alterations in drug disposition and clearance due to obesity. Journal of Pharmacology and Experimental Therapeutics 217: 681–685, 1981a PubMedCAS Google Scholar
Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam and acetaminophen. Journal of Laboratory and Clinical Medicine 101: 873–880, 1983 PubMedCAS Google Scholar
Abernethy DR, Greenblatt DJ, Divoll M, Smith RB, Shader RT. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clinical Pharmacokinetics 9: 177–183, 1984b ArticlePubMedCAS Google Scholar
Abernethy DR, Greenblatt DJ, Mathis R, Gugler R. Cimetidine disposition in obesity. American Journal of Gastroenterology 79: 91–94, 1984a PubMedCAS Google Scholar
Abernethy DR, Greenblatt DJ, Smith RW. Digoxin disposition in obesity: clinical pharmacokinetic investigation. American Heart Journal 102: 740–744, 1981b ArticlePubMedCAS Google Scholar
Abernethy DR, Todd EL, Schwartz JB. Caffeine disposition in obesity. British Journal of Clinical Pharmacology 20: 61–66, 1985 ArticlePubMedCAS Google Scholar
Adler M, Schaffner F. Fatty liver, hepatitis and cirrhosis in obese patients. American Journal of Medicine 67: 811–816, 1979 ArticlePubMedCAS Google Scholar
Akera T, Brody TM. The role of the Na+, K+, ATPase in the inotropic action of digitalis. Pharmacology Reviews 29: 187–220, 1978 Google Scholar
Alexander JK, Dennis EW, Smith WG, Amad KH, Duncan WC, et al. Blood volume, cardiac output and distribution of systemic blood flow in extreme obesity. Cardiovascular Research Centre Bulletin 1: 39–44, 1962 Google Scholar
Aro A, Anttila M, Korhonen T, Sundquist H. Pharmacokinetics of propranolol and Sotalol in hyperthyroidism. European Journal of Clinical Pharmacology 21: 373–377, 1982 ArticlePubMedCAS Google Scholar
Backman L, Beerman B, Groschinsky-Grind M, Hallberg D. Malabsorption of hydrochlorothiazide following intestinal shunt surgery. Clinical Pharmacokinetics 4: 63–68, 1979 ArticlePubMedCAS Google Scholar
Barry MG, Collins WCJ, Feely J. Plasma protein binding of drugs in insulin dependent diabetes mellitus. British Journal of Pharmacology 89: 719p, 1986 Article Google Scholar
Bauer LA, Edwards WAD, DeHuger EP, Sinonowitz DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and markedly obese patients. European Journal of Clinical Pharmacology 24: 643–647, 1983 ArticlePubMedCAS Google Scholar
Bauer LA, Wareing-Tranc, Edwards WAD, Raisys V, Ferneri L, et al. Cimetidine clearance in the obese. Clinical Pharmacology and Therapeutics 37: 425–430, 1985 ArticlePubMedCAS Google Scholar
Bell JM, Russell CJ, Nelson JK, Kelly JG, McDevitt DG. Studies on the effect of thyroid dysfunction on the elimination of the _β_-adrenoceptor blocking drugs. British Journal of Clinical Pharmacology 4: 79–82, 1977 ArticlePubMedCAS Google Scholar
Benedech TH, Blouin RAS, McNamara PJ. Serum protein binding and the role of the increased _α_-1-acid glycoprotein in moderately obese male subjects. British Journal of Clinical Pharmacology 18: 941–946, 1984 Article Google Scholar
Berman ML, Kuhnert L, Phythyon JM, Holaday DA. Isoflurane and enflurane induced hepatic necrosis in triiodothyronine pretreated rats. Anaesthesiology 58: 1–5, 1983 ArticleCAS Google Scholar
Bianchi R, Zucchelli GC, Giannessi D, Pilo A, Marian G, et al. Evaluation of triiodothyronine (T3) kinetics in normal subjects, in hypothyroid and hyperthyroid patients using specific antiserum for the determination of labeled T3 in plasma. Journal of Clinical Endocrinology and Metabolism 46: 203–214, 1978 ArticlePubMedCAS Google Scholar
Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrobial Agents and Chemotherapy 21: 575–580, 1982 ArticlePubMedCAS Google Scholar
Bodansky HJ, Drury PL, Cudworth AG, Evans DAP. Acetylator phenotypes and type I (insulin dependent) diabetics with microvascular disease. Diabetes 30: 907–910, 1981 ArticlePubMedCAS Google Scholar
Bonelli J, Haydl H, Hruby K, Kark G. The pharmacokinetics of digoxin in patients with manifest hyperthyroidism after normalisation of thyroid function. International Journal of Clinical Pharmacology and Biopharmaceutics 16: 302–306, 1978 CAS Google Scholar
Bowman SL, Hudson SA, Simpson G, Munro JF, Clements JA. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. British Journal of Clinical Pharmacology 21: 529–532, 1986 ArticlePubMedCAS Google Scholar
Bradley SE, Stephens FC, Coelho JB, Reulle P. The thyroid and the kidney. Kidney International 6: 346–365, 1974 ArticlePubMedCAS Google Scholar
Breckenridge A, Burke CW, Davies DS, Orme ML’E. Immediate decrease by hydrocortisone of the plasma half life of antipyrine. British Journal of Pharmacology 47: 434–436, 1973 ArticlePubMedCAS Google Scholar
Burrows AW, Hockaday TDR, Mann JI, Taylor JG. Diabetic dimorphism according to acetylator status. British Medical Journal 1: 208–210, 1978. ArticlePubMedCAS Google Scholar
Christoff PB, Conti DR, Naylor C, Juskco WJ. Procainamide disposition in obesity. Drug Intelligence and Clinical Pharmacy 17: 516–522, 1983 PubMedCAS Google Scholar
Cohen P, Barzilai N, Karmeli E. Correlation between insulin clearance and insulin responsiveness: studies in normal, obese, hyperthyroid and Cushing’s Syndrome patients. Metabolism 35: 744–749, 1986 ArticlePubMedCAS Google Scholar
Crooks J, Hedley SJ, MacNee C, Stevenson IH. Changes in drug metabolising activity in thyroid disease. British Journal of Pharmacology 49: 156–157P, 1973 Google Scholar
Croxon MS, Ibbertson HK. Serum digoxin in patients with thyroid disease. British Medical Journal 3: 566–568, 1975 Article Google Scholar
Curfman GD, Crowley TJ, Smith TW. Thyroid induced alterations in myocardial sodium and potassium activated adenosine triphosphate, monovalent active transport and cardiac glycoside binding. Journal of Clinical Investigation 59: 586–590, 1977 ArticlePubMedCAS Google Scholar
Dahlstrom CG, Ladefogged SD. Verapamil in atrial fibrillation in hyperthyroidism. British Medical Journal 294: 1384, 1987 ArticlePubMedCAS Google Scholar
Daintith H, Stevenson IH, O’Malley K. Influence of diabetes mellitus on drug metabolism in man. International Journal of Clinical Pharmacology 13: 55–58, 1976 CAS Google Scholar
Dajani RM, Kayyali S, Satteb SE, Birbari A. A study of the physiological disposition of acetophenetidin by the diabetic man. Comparative and General Pharmacology 5: 1–9, 1974 ArticlePubMedCAS Google Scholar
Dimitriadis G, Baker B, Marsh H, Mandarino R, Rizza R, et al. Effect of thyroid hormone excess on action secretion and metabolism of insulin in humans. American Journal of Physiology 248 (Suppl.): F593–F601, 1985 Google Scholar
Dionne RE, Bauer LA, Gibson GA, Griffin WO, Blouin RA. Estimating creatinine clearance in morbidly obese patients. American Journal of Hospital Pharmacy 38: 841–844, 1981 PubMedCAS Google Scholar
Doherty JE, Perkins NH. Digoxin metabolism in hypo and hyperthyroidism: studies with tritiated digoxin in thyroid disease. Annals of Internal Medicine 64: 489–507, 1966 PubMedCAS Google Scholar
Dundee JW. The influence of body weight, sex and age on the dosage of thiopentone. British Journal of Anaesthesia 26: 164–173, 1954 ArticlePubMedCAS Google Scholar
Eichelbaum M. Drug metabolism in thyroid disease. Clinical Pharmacokinetics 1: 339–350, 1976 ArticlePubMedCAS Google Scholar
Eichelbaum MG, Bodem R, Gugler C, Schneider-Deters C, Dengler HJ. Influence of thyroid status on plasma half life of antipyrine in man. New England Journal of Medicine 290: 1040–1042, 1974 ArticlePubMedCAS Google Scholar
Eichelbaum M, Bodem G, Schneide-Deiters C. Antipyrine half life time, antipyrine metabolism and thyroid function in man. Naunyn-Schmiedebergs Archives of Pharmacology 277 (Suppl.): R14, 1973 Google Scholar
Eichenbusch W, Lahrtz HG, Seppelt U, Van Zwieten PA. Serum concentration and urinary excretion of 3H-oubain and 3H digitoxin in patients suffering from hyperthyroidism or hypothyroidism. Klinische Wochenschrift 48: 270–275, 1970 Article Google Scholar
Ewy GA, Groves BM, Ball MF, Nimmo L, Jackson B, et al. Digoxin metabolism in obesity. Circulation 44: 810–814, 1971 ArticlePubMedCAS Google Scholar
Feely J. Clinical pharmacokinetics of β adrenoceptor blocking drugs in thyroid disease. Clinical Pharmacokinetics 8: 1–16, 1983 ArticlePubMedCAS Google Scholar
Feely J, Crooks J, Forrest AL, Hamilton WP, Gunn A. Propranolol in the surgical treatment of hyperthyroidism, including severely thyrotoxic patients. British Journal of Surgery 68: 865–869, 1981e ArticlePubMedCAS Google Scholar
Feely J, Crooks J, Stevenson IH. Alterations in plasma propranolol steady state concentration in thyroid disease. Clinical Pharmacology and Therapeutics 23: 112–113, 1978 Google Scholar
Feely J, Crooks J, Stevenson IH. Plasma propranolol steady state concentrations in thyroid disorders. European Journal of Clinical Pharmacology 19: 329–333, 1981a ArticlePubMedCAS Google Scholar
Feely J, Crooks J, Stevenson IH. The influence of age, smoking and hyperthyroidism on plasma propranolol steady state concentration. British Journal of Clinical Pharmacology 12: 73–78, 1981d ArticlePubMedCAS Google Scholar
Feely J, Forrest A, Gunn A, Hamilton W, Stevenson I, et al. Propranolol dosage in thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism 51: 658–661, 1980 ArticlePubMedCAS Google Scholar
Feely J, Peden N. Use of _β_-adrenoceptor blocking drugs in hyperthyroidism. Drugs 27: 425–446, 1984 ArticlePubMedCAS Google Scholar
Feely J, Stevenson IH, Crooks J. Increased clearance of propranolol in thyrotoxicosis. Annals of Internal Medicine 94: 472–474, 1981b PubMedCAS Google Scholar
Feely J, Stevenson IH, Crooks J. Altered plasma protein binding of drugs in thyroid disease. Clinical Pharmacokinetics 6: 298–305, 1981c ArticlePubMedCAS Google Scholar
Flanagan RJ, Richens A. The influence of elevated plasma hydrocortisone concentrations on antipyrine metabolism in man. British Journal of Pharmacology 1: 409–412, 1974 ArticleCAS Google Scholar
Fletcher P, Hirji MR, Kuhn S, Alexander L, Mucklow JC. The effects of diabetes mellitus, exercise and single doses of biguanides upon lactate metabolism in man. British Journal of Clinical Pharmacology 21: 691–699, 1986 ArticlePubMedCAS Google Scholar
Forfar JC, Muir AL, Toft AD. Influence of thyroid hormones on left ventricular function: evidence for impairment of myocardial contractility in both hyper- and hypothyroidism. Annales d’Endocrinologie 43: 42A, 1982 Google Scholar
Forfar JC, Pottage A, Toft AD, Irvine WJ, Clements JA, et al. Paracetamol pharmacokinetics in thyroid disease. European Journal of Clinical Pharmacology 18: 269–273, 1980 ArticlePubMedCAS Google Scholar
Gai P, Jusko WJ, Yurchah AM, Franklin BA. Theophylline disposition in obesity. Clinical Pharmacology and Therapeutics 23: 438–449, 1978 Google Scholar
Gallagher TF, Hellman L, Finkelstein J, Yoshida K, Weitzman ED, et al. Hyperthyroidism and Cortisol secretion in man. Journal of Clinical Endocrinology and Metabolism 34: 919–927, 1972 ArticlePubMedCAS Google Scholar
Gilfrich HJ. Untersuchungen zur Pharmacokinetik von Digoxin bei hyperthyreoten Patienten. Verhandlungen der Deutschen Gesellschaft für innere Medizin 82: 1726–1728, 1976 PubMed Google Scholar
Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61: 27–35, 1984 PubMedCAS Google Scholar
Hallengren B, Nilsson OR, Karlberg BE, Melander A, Tegler L, et al. Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol. European Journal of Clinical Pharmacology 21: 379–384, 1982 ArticlePubMedCAS Google Scholar
Hansen JM, Skovsted L, Kampman JP, Lumholtz EI, Siersbaek-Nielsen K. Unaltered metabolism of Phenytoin in thyroid disorders. Acta Pharmacologica et Toxicologica 42: 343–346, 1978 Article Google Scholar
Haynes RC, Murad F. Thyroid and antithyroid drugs. In Goodman & Gilman (Eds) The pharmacological basis of therapeutics, 7th ed., p. 1394, Macmillan, New York, 1985 Google Scholar
Hissin JP, Foley JE, Wardzala LJ, Karnieli E, Simpson IA, et al. Mechanism of insulin resistant glucose transport activity in the enlarged adipose cell of the aged obese rat. Journal of Clinical Investigation 70: 780–790, 1982 ArticlePubMedCAS Google Scholar
Ingbar SH, Frunhel N. Studies of thyroid function and the peripheral metabolism of I131 labelled thyroxine in patients with treated Graves Disease. Journal of Clinical Investigation 37: 1603–1614, 1958 ArticlePubMedCAS Google Scholar
Jung D, Mayersohn M, Perrier D, Calkins J, Saunders R. Thiopental disposition in lean and obese patients undergoing surgery. Anesthesiology 56: 265–274, 1982 Google Scholar
Kadar D, Inaba T, Endrenyl L, Johnson GE, Kalow W. Comparative drug elimination capacity in man: glutethimide, amobarbital, antipyrine and sulfinpyrazone. Clipical Pharmacology and Therapeutics 14: 552–560, 1973 CAS Google Scholar
Kampman JP, Klein H, Lumholtz B, Molholm-Hansen JE. Ampicillin and propylthiouracil pharmacokinetics in intestinal bypass patients followed up to a year after operation. Clinical Pharmacokinetics 9: 168–176, 1984 Article Google Scholar
Kampman J, Skovsted L. The pharmacokinetics of propylthiouracil in hyperthyroidism. Acta Pharmacologica et Toxicologica 37: 201–210, 1975 Article Google Scholar
Kemp SF, Kearns GL, Turley CP. Altered Phenytoin binding in children with diabetes. Clinical Pharmacology and Therapeutics 41: 170, 1987 Google Scholar
Kimberg DV. Liver. In Werner & Ingbar (Eds) The thyroid, pp. 569–573, Harper & Row, New York, 1971 Google Scholar
Korhonen T, Uusitupa M, Voutilainen E, Sarlund H, Laakso M, et al. Lack of effect of hepatic enzyme induction on metabolic control in patients with type II (non insulin dependent) diabetes. Clinical Pharmacology and Therapeutics 41: 633–638, 1987 ArticlePubMedCAS Google Scholar
Kristensen MB. Medikament — medikament interaction. Thesis, 1973. F.A.D.L. Quoted in Shenfield GM. Influence of thyroid dysfunction on drug pharmacokinetics. Clinical Pharmacokinetics 6: 275–279, 1981 Article Google Scholar
Lamberg B. Glucose metabolism in thyroid disease. Acta Medica Scandinavica 178: 351–362, 1965 ArticlePubMedCAS Google Scholar
Lawrence JR, Sumner DJ, Kalk WJ, Ratcliffe WA, Whiting B, et al. Digoxin kinetics in patients with thyroid dysfunction. Clinical Pharmacology and Therapeutics 22: 7–13, 1977 PubMedCAS Google Scholar
Lerner PI, Weinstein L. Abnormalities of absorption of benzylpenicillin G and sulfisoxazole in patients with diabetes mellitus. American Journal of the Medical Sciences 248: 37–51, 1964 ArticlePubMedCAS Google Scholar
Levine HD. Compromise therapy in the patient with angina pectoris and hypothyroidism: a clinical assessment. American Journal of Medicine 69: 411–418, 1980 ArticlePubMedCAS Google Scholar
Levy G, MacGillivray MH, Procknal JA. Riboflavine absorption in children with thyroid disorders. Pediatrics 50: 896–900, 1972 PubMedCAS Google Scholar
MacNee C, Headley AJ, Adumson DG, Crooks J. Drug metabolising capacity in thyroid disease. Israel Journal of Medical Science 8: 1889–1890, 1972 Google Scholar
Madacsy L, Bokor M, Kozcsa G. Carbenicillin half life in children with early diabetes mellitus. International Journal of Clinical Pharmacology and Biopharmacy 14: 155–158, 1976 PubMedCAS Google Scholar
Manger WM, Gifford Jr RW. Pheochromocytoma: diagnosis and management. New York State Journal of Medicine 80: 216–226, 1980 PubMedCAS Google Scholar
Marcus FI, Horton H, Jacobs S, Pippin S, Stafford M, et al. The effect of jejunoileal bypass in patients with morbid obesity on the pharmacokinetics of digoxin in man. American Journal of Cardiology 37: 154, 1976 Article Google Scholar
McDevitt DG. Propranolol in the treatment of thyrotoxicosis: a review. Postgraduate Medical Journal 52 (Suppl. 4): 157–161, 1976 PubMed Google Scholar
Mcintosh TJ, Brunk SF, Koln I, Fouts JR, Wilson WR. Increased sensitivity to warfarin in thyrotoxicosis. Journal of Clinical Investigation 49: 63a–64a, 1970 Article Google Scholar
McLaren EH, Burden AC, Moorhead PJ. Acetylator phenotype in diabetic neuropathy. British Medical Journal 2: 291–293, 1977 ArticlePubMedCAS Google Scholar
Miller LJ, Gorman CA, Go VL. Gut-thyroid interrelationships. Gastroenterology 75: 901–911, 1978 PubMedCAS Google Scholar
Milsap RL, Plaisance KI, Jusko WJ. Prednisolone disposition in obese men. Clinical Pharmacology and Therapeutics 36: 824–831, 1984 ArticlePubMedCAS Google Scholar
Miners JO, Grgurinovich N, Whitehead AG, Robson RA, Birkett DJ. Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid. British Journal of Clinical Pharmacology 22: 135–142, 1986 ArticlePubMedCAS Google Scholar
Morrison MH, Hawksworth GM. Glucaric acid conjugation by hepatic microsomal fractions isolated from streptozotocin-induced diabetic rats. Biochemical Pharmacology 33/23: 3833–3838, 1984 Article Google Scholar
Morrow DH, Gaffney TE, Braunwald E. Studies on digitalis VII: influence of hyper and hypothyroidism on the myocardial response to ouabain. Journal of Pharmacology and Experimental Therapeutics 140: 324–328, 1963 CAS Google Scholar
Murkami K, Kasama T, Hayashi R, Tsuskima M, Nishioheda Y, et al. Myxoedema coma induced by beta-adrenoceptor blocking agent. British Medical Journal 285: 543–544, 1982 Article Google Scholar
Myers JD, Brannon ES, Holland BC. A correlative study of the cardiac output and the hepatic circulation in hyperthyroidism. Journal of Clinical Investigation 29: 1069–1077, 1950 ArticlePubMedCAS Google Scholar
Ochs HR, Greenblatt DJ, Kaschell HJ, Klehr U, Divoll M, et al. Diazepam kinetics in patients with renal insufficiency or hyperthyroidism. British Journal of Clinical Pharmacology 12: 829–832, 1981 ArticlePubMedCAS Google Scholar
Olefsky JM, Kolterman OG. Mechanism of insulin resistance in obesity and non insulin dependent diabetes. American Journal of Medicine 70: 151–169, 1981 ArticlePubMedCAS Google Scholar
Oyama T, Taniguchi K, Ishihara H, Matsuki A, Haida A, et al. Effects of enflurane anaesthesia and surgery on endocrine function in man. Acta Anaesthiologica Scandinavica (Suppl.) 71: 32–38, 1979 ArticleCAS Google Scholar
Park BK. Assessment of urinary 6 beta-hydroxycortisol as an in vivo index of mixed function oxidase activity. British Journal of Clinical Pharmacology 12: 97–102, 1981 PubMedCAS Google Scholar
Peterson RE. The influence of the thyroid on adrenal-cortical function. Journal of Clinical Investigation 37: 736–743, 1958 ArticlePubMedCAS Google Scholar
Pirttiaho HI, Salmela PI, Sotaniemi EA, Pelkonen RO, Pitkanen U, et al. Drug metabolism in diabetic subjects with fatty livers. British Journal of Clinical Pharmacology 18: 895–899, 1984 ArticlePubMedCAS Google Scholar
Pontiroli AE, Mosca A, de Pasqua A, Alcini D, Pozza G. The fast acetylator phenotype in diabetes mellitus, abnormal prevalence and association with the ABO groups. Diabetologia 27: 235–237, 1984 PubMedCAS Google Scholar
Redmond GP, Bell JJ, Penel JM. Effect of human growth hormone on amobarbital metabolism in children. Clinical Pharmacology and Therapeutics 24: 213–218, 1978 PubMedCAS Google Scholar
Redmond GP, Nichola PS, Bell JJ. The growth hormone effect on human drug metabolism: opposite effects on different substrates. Abstract. Pediatric Research 13: 373, 1979 Google Scholar
Riddell JG, Neill JD, Kelly JG, McDevitt DG. Effects of thyroid dysfunction on propranolol kinetics. Clinical Pharmacology and Therapeutics 28: 565–574, 1980 ArticlePubMedCAS Google Scholar
Rifkind AB, Saenger P, Levine LS, Pareira J, New MI. Effects of growth hormone on antipyrine kinetics in children. Clinical Pharmacology and Therapeutics 30: 127–132, 1981 ArticlePubMedCAS Google Scholar
Rubenfeld S, Silverman VE, Welch KMA, Mallette LE, Kohler PO. Propranolol pharmacokinetics in thyrotoxicosis. Clinical Research 26: 295A, 1978 Google Scholar
Ruiz-Cabello F, Erill S. Abnormal serum protein binding of acidic drugs in diabetes mellitus. Clinical Pharmacology and Therapeutics 36: 691–695, 1984 ArticlePubMedCAS Google Scholar
Saenger P, Rifkind AB, New MI. Changes in drug metabolism in children with thyroid disorders. Journal of Clinical Endocrinology and Metabolism 42: 155–159, 1976 ArticlePubMedCAS Google Scholar
Sawin CT, Chopra D, Azizi F, Mannix JE, Bacharach P. The aging thyroid. Journal of the American Medical Association 242: 247–250, 1979 ArticlePubMedCAS Google Scholar
Schaaf M, Payne CA. Dystonic reactions to prochlorperazine in hypoparathyroidism. New England Journal of Medicine 275: 991–995, 1966 ArticlePubMedCAS Google Scholar
Schrogie JJ, Solomon HM. The anticoagulant response to bishydroxycoumarin 11: the effect of D-thyroxine, Clofibrate and norethandrilone. Clinical Pharmacology and Therapeutics 8: 70–77, 1967 PubMedCAS Google Scholar
Schwartz SN, Prazin GJ, Lyon JA, Ho M, Pascalle AW. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. Journal of the Infectious Diseases 138: 499–505, 1978 ArticleCAS Google Scholar
Scott AK, Khir ASM, Bewsher PD, Hawksworth GM. Oxazepam pharmacokinetics in thyroid disease. British Journal of Clinical Pharmacology 17: 49–53, 1984 ArticlePubMedCAS Google Scholar
Servin FF, Nivoche Y, Desmonts JM, Rice SA, Mazze RI. Biotransformation of halothane and enflurane with hyperthyroidism. Anaesthesiology 64: 387–391, 1986 ArticleCAS Google Scholar
Shenfield GM. Influence of thyroid dysfunction on drug pharmacokinetics. Clinical Pharmacokinetics 6: 275–297, 1981 ArticlePubMedCAS Google Scholar
Shenfield GM, McCann VJ, Tjokresetio R. Acetylation status and diabetic neuropathy. Diabetologia 22: 441–444, 1982 ArticlePubMedCAS Google Scholar
Shenfield GM, Thompson J, Horn DB. Plasma and urinary digoxin in thyroid dysfunction. European Journal of Clinical Pharmacology 12: 437–443, 1977 ArticlePubMedCAS Google Scholar
Shively CA, di Gagliar CL, Hartshorn RD, Vesell ES. Failure of hydrocortisone to alter acutely antipyrine disposition. Clinical Pharmacology and Therapeutics 23: 408–413, 1978 PubMedCAS Google Scholar
Simone JV, Abildgaard CF, Schulman I. Blood coagulation in thyroid dysfunction. New England Journal of Medicine 273: 1057–1061, 1965 ArticlePubMedCAS Google Scholar
Sobel BE, Braunwald E. Hyperthyroidism — cardiovascular system. In Werner & Ingbar (Eds) The thyroid, 3rd ed., p. 552, Harper & Row, New York, 1971 Google Scholar
Sotaniemi EA, Arranto AJ, Sutinen S, Stengard JH, Sutinen S. Treatment of non-insulin dependent diabetes mellitus with enzyme inducers. Clinical Pharmacology and Therapeutics 33: 826–834, 1983 ArticlePubMedCAS Google Scholar
Staffurth J, Gibberd MD, Tang Fui SNG. Arterial embolisation in thyrotoxicosis with atrial fibrillation. British Medical Journal 2: 688–690, 1977 ArticlePubMedCAS Google Scholar
Strauch G, Weber S, de Lauture D, Frangin G, Dorfman P, et al. Changes in human growth hormone (hGH) kinetics after short term administration. Clinical Pharmacology and Therapeutics 41: 198, 1987 Google Scholar
Thomas FB, Caldwell JH, Greenberger NJ. Steatorrhoea in thyrotoxicosis: relation to hypermotility and excessive dietary fat. Annals of Internal Medicine 78: 669–675, 1973 PubMedCAS Google Scholar
United States Chartbook. Health, DHEW publication no. (HRA) 77-1233, US Government Printing Offices, Washington D.C., 1977
Veroni M, Shenfield GM. The influence of thyroid function on ouabain accumulation by the rat heart. Pharmacological Research Communications 12: 769–779, 1980 ArticlePubMedCAS Google Scholar
Vesell ES, Shapiro JR, Passananti GT, Jogensen H, Shively CA. Altered plasma half lives of antipyrine propylthiouracil and methimazole in thyroid dysfunction. Clinical Pharmacology and Therapeutics 17: 48–56, 1975 PubMedCAS Google Scholar
Vozeh S, Otten M, Staub JJ, Follath F. Influence of thyroid function on theophylline kinetics. Clinical Pharmacology and Therapeutics 36: 634–640, 1984 ArticlePubMedCAS Google Scholar
Wahlin Boll E, Almer LO, Melander A. Bioavailability, pharmacokinetics and effects of glipizide in type II diabetes. Clinical Pharmacokinetics 7: 363–372, 1982 ArticlePubMedCAS Google Scholar
Walters MB. The relationship between thyroid function and anticoagulant therapy. American Journal of Cardiology 11: 112–114, 1963 ArticlePubMedCAS Google Scholar
Watters K, Tomkin GH. Serum digoxin in patients with thyroid disease. British Medical Journal 4: 102, 1975 ArticlePubMedCAS Google Scholar
Wells PG, Feely J, Wilkinson GR, Wood AJJ. Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long term dosing. Clinical Pharmacology and Therapeutics 33: 603–608, 1983 ArticlePubMedCAS Google Scholar
Wilkinson R, Burr WA. A comparison of propranolol and nadolol pharmacokinetics and clinical effects in thyrotoxicosis. American Heart Journal 108: 1160–1167, 1984 ArticlePubMedCAS Google Scholar
Wood GM, Waters AK. Prolonged dystonic reaction to chlorpromazine in myxoedema coma. Postgraduate Medical Journal 56: 192–193, 1980 ArticlePubMedCAS Google Scholar
Yamaji T, Motohasih S, Murakawa S, Ibayashi H. Urinary excretion of 6 _β_-hydroxycortisol in states of altered thyroid function. Journal of Clinical Endocrinology 29: 801–806, 1969 ArticleCAS Google Scholar